Treatment of Multiple Sclerosis with Cyclophosphamide

  • Glenn A. Mackin
  • David M. Dawson
  • David A. Hafler
  • Howard L. Weiner
Part of the Clinical Medicine and the Nervous System book series (CLIN.MED.NERV.)


Multiple sclerosis (MS) is an inflammatory disease of the central nervous system of presumed autoimmune etiology. A number of immune abnormalities have been described in the disease including loss of suppressor influences and activated T- and B-cells both in the central nervous system and the periphery (Hafler and Weiner 1989). The majority of immunotherapeutic approaches studied over the past 20 years have been designed to suppress the immune system in MS. This has included attempts at both antigen-specific and antigen non-specific suppression (Weiner and Hafler 1988).


Multiple Sclerosis Multiple Sclerosis Patient Lupus Nephritis Plasma Exchange Expand Disability Status Scale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aimard G, Girard PF, Raveau J et al. (1966) Sclerose et plaques et processus d’autoimmunisation. Traitement par les anti-mitotiques. Lyon Med 215: 345–352Google Scholar
  2. Bahr U, Schulten HR, Hommes OR, Aerts F (1980) Determination of cyclophosphamide in urine, serum and cerebrospinal fluid of multiple sclerosis patients by field desorption mass spectrometry. Clin Chim Acta 103: 183–192PubMedCrossRefGoogle Scholar
  3. Balow JE, Austin HA, Tsokos GC, Antonovych TT, Steinberg AD, Klipper JH (1987) Lupus nephritis. Ann Int Med 106: 79–94PubMedGoogle Scholar
  4. Brinkman CJJ, Nillesen WM, Hommes OR (1983) T-cell subpopulations blood and cerebrospinal fluid of multiple sclerosis patients: effect of cyclophosphamide. Clin Immun Immunopathol 29: 341–348CrossRefGoogle Scholar
  5. Brinkman CJJ, Nillesen WM, Hommes OR (1984) The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis. Acta Neurol Scand 69: 90–96PubMedCrossRefGoogle Scholar
  6. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL (1988) Immunosuppression with high-dose cyclophosphamide and ACTH in progressive multiple sclerosis: Cumulative 6-year experience in 164 patients. Neurology (Suppl 2 ) 38: 9–14Google Scholar
  7. Cendrowski W (1973) Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuc cinate with cyclophosphamide or cytosine arabinoside. Acta Neurol Belg 73: 209–219PubMedGoogle Scholar
  8. Drachman DA (1975) Cyclophosphamide in exacerbations of multiple sclerosis: Therapeutic trial and a strategy for pilot drug studies. Neurol Neurosurg Psychiatry 38: 592–597CrossRefGoogle Scholar
  9. Fox DA, McCune WJ (1989) Immunologic and clinical effects of cytotoxic drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus. Concepts Immunopathol, Basel, Karger 7: 20–78Google Scholar
  10. Girard PF, Aimard G, Pellett H (1967) Immunodepressive therapy in neurology. Presse Med 75: 967–968PubMedGoogle Scholar
  11. Gonsette RE, Demonty L, Delmotte P (1977) Intensive immunosuppression with cyclophosph- amide in multiple sclerosis. Follow up of 100 patients for 2–6 years. J Neurol 214: 173–181PubMedCrossRefGoogle Scholar
  12. Gonsette RE, Demonty L, Delmotte P (1980) Intensive immunosuppression with cyclophosphamide in remittent forms of multiple sclerosis. A follow-up of 134 patients for 2–10 years. In: Bauer HJ, Poser S, Ritter G (eds) Progress in Multiple Sclerosis Research. Springer-Verlag, Berlin, pp 401–406CrossRefGoogle Scholar
  13. Goodkin DE, Plencner S, Palmer-Saxerud J, Teetzen M, Hertsgaard D (1987) Cyclophosphamide in chronic progressive multiple sclerosis: Maintenance vs. nonmaintenance therapy. Arch Neurol 44: 823–827Google Scholar
  14. Hafler DA, Orav J, Gertz R, Stazzone L, Weiner HL (1991) Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol 32: 149–158PubMedCrossRefGoogle Scholar
  15. Hafler DA, Weiner HL (1989) MS: a CNS and systemic autoimmune disease. Immunol Today 10: 104–107PubMedCrossRefGoogle Scholar
  16. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL (1983) Intensive immunosuppression in progressive multiple sclerosis: A randomized, three-arm study of high-dose cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308: 173–180Google Scholar
  17. Hommes OR, Prick JJG, Lamers KJB (1975) Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 78: 59–73PubMedCrossRefGoogle Scholar
  18. Hommes OR, Lamers KJB, Reekers P (1980a) Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 223: 177–190CrossRefGoogle Scholar
  19. Hommes OR, Lamers KJB, Reekers P (1980b) Prognostic factors in intensive immunosuppressive treatment of chronic progressive MS. In: Bauer HJ, Poser S, Ritter G (eds) Progress in Multiple Sclerosis Research. Springer-Verlag, Berlin, pp 396–400CrossRefGoogle Scholar
  20. Kaldor JM, Day NE, Pettersson F et al. (1990) Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322: 1–6PubMedCrossRefGoogle Scholar
  21. Killian JM, Bressler RB, Armstrong RM, Huston DP (1988) Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol 45: 27–30PubMedGoogle Scholar
  22. Lamers KJB, Uitdehaag BMJ, Hommes OR, Doesburg W, Wevers RA, Geel WJA (1988) The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 51: 1334–1337PubMedCrossRefGoogle Scholar
  23. Likosky WH (1988) Experience with cyclophosphamide in multiple sclerosis: The cons. Neurology 38 (suppl 2): 14–19PubMedGoogle Scholar
  24. Mackin GA, Weiner HL, Orav J et al. (1991) IV cyclophosphamide/ACTH plus maintenance cyclophosphamide boosters in progressive MS: final report of the Northeast Cooperative Treatment Group. Neurology 41 (suppl 1): 147Google Scholar
  25. Mauch E, Kornhuber HH, Pfrommer U, Hahnel A, Laufen H, Krapf H (1989) Effective treatment of chronic progressive multiple sclerosis with low-dose cyclophosphamide with minor side-effects. Eur Arch Psychiatr Neurol Sci 238: 115–117CrossRefGoogle Scholar
  26. McCune WJ, Golbus J; Zeldes W et al. (1988) Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318: 1423–1431Google Scholar
  27. Mickey MR, Ellison GW, Fahey JL, Moody DJ, Myers LW (1987) Correlation of clinical and immunological states in multiple sclerosis. Arch Neurol 44: 371–375PubMedGoogle Scholar
  28. Millac M, Miller H (1969) Cyclophosphamide in multiple sclerosis. Lancet 1: 783PubMedCrossRefGoogle Scholar
  29. Moody DJ, Fahey JL, Grable E, Ellison GW, Myers LW (1987) Administration of monthly pulses of cyclophosphamide in multiple sclerosis patients: delayed recovery of several immune parameters following discontinuation of long-term cyclophosphamide treatment. J Neuroimmunol 14: 175–182PubMedCrossRefGoogle Scholar
  30. Moody DJ, Kagan J, Liao D, Ellison GW, Myers LW (1978) Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients: effects of long-term treatment on immunologic parameters. J Neuroimmunol 14: 161–173CrossRefGoogle Scholar
  31. Myers LW, Fahey JL, Moody DJ, Mickey MR, Frane MV, Ellison GW (1987) Cyclophosphamide “pulses” in chronic progressive multiple sclerosis: Arch Neurol 44: 828–832PubMedGoogle Scholar
  32. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC, and the Canadian Cooperative MS Group (1990) Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems ( FS) in a multiple sclerosis clinical trial. Neurology 40: 971–975Google Scholar
  33. The Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian Cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337: 442–446Google Scholar
  34. The Multiple Sclerosis Study Group (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 27: 591–605CrossRefGoogle Scholar
  35. Theys P, Gosseye-Lissoir F, Ketelaer P, Carton H (1981) Short-term intensive cyclophosphamide treatment in multiple sclerosis: A retrospective controlled study. J Neurol 225: 119–133PubMedCrossRefGoogle Scholar
  36. Thompson AJ, Kermode AG, MacManus DG (1990) Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. Br Med J 300: 631–634CrossRefGoogle Scholar
  37. Thompson AJ, Kermode AG, Loicks D (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29: 53–62PubMedCrossRefGoogle Scholar
  38. Uitdehaag BMJ, Nillesen WM, Hommes OR (1989) Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid. Acta Neurol Scand 79: 12–17PubMedCrossRefGoogle Scholar
  39. Weiner HL, Hauser SL, Dawson DM, Hafler DA, Mackin GA, Orav EJ (1991) Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 337: 1033–1034CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1992

Authors and Affiliations

  • Glenn A. Mackin
  • David M. Dawson
  • David A. Hafler
  • Howard L. Weiner

There are no affiliations available

Personalised recommendations